PT  - JOURNAL ARTICLE
AU  - Bangma, Amber
AU  - Pibiri, Paola
AU  - Sun, Shiqiang
AU  - De Jong, Sofie
AU  - Bigaeva, Emilia
AU  - Björk, Johannes R.
AU  - Karmi, Naomi
AU  - Verstappen, Gwenny M.P.J.
AU  - Kroese, Frans G.M.
AU  - Kats-Ugurlu, Gursah
AU  - Hermoso, Marcela A.
AU  - Vila, Arnau Vich
AU  - van der Wijst, Monique G.P.
AU  - Faber, Klaas N.
AU  - Weersma, Rinse K.
AU  - Uniken Venema, Werna T.C.
AU  - Festen, Eleonora A.M.
TI  - Inflammatory Bowel Disease in patients with Primary Sclerosing Cholangitis: a distinct form of colitis
AID  - 10.1101/2024.07.23.24310848
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.07.23.24310848
4099  - http://medrxiv.org/content/early/2024/07/23/2024.07.23.24310848.short
4100  - http://medrxiv.org/content/early/2024/07/23/2024.07.23.24310848.full
AB  - Background and aims Primary sclerosing cholangitis (PSC) is an inflammatory disorder of the bile ducts, often accompanied by inflammatory bowel disease (PSC-IBD). Substantial differences in clinical presentation are observed between PSC-IBD and ulcerative colitis (UC). In this study we aim to find distinct pathomechanisms for PSC-IBD using single-cell mRNA sequencing.Methods Forty-seven colonic mucosal biopsies of PSC-IBD (n=24), UC (n=18) (where possible matched inflamed (I) non-inflamed (NI)), and non-IBD subjects (n=5) were collected and dissociated. Library preparation and processing for sequencing was followed by differential abundance, differential expression, and cell-cell-interaction analyses. Stainings for DUOX2 and HLA-DR were applied on tissue sections.Results In total, 71,798 cells comprised 54 distinct cell types, including a new cell type: the DUOX2+ enterocyte, mainly present in inflamed colon and acting as antigen presenting cells (HLA-DR+). Stem cells exhibited increased abundances in PSC-NI but not in UC-NI. Additionally, we found distinct gene expression profiles in PSC and UC which were related to inflammation: while mainly inflammatory monocytes were activated in PSC inflammation, and inflammatory fibroblasts were activated in UC inflammation.Conclusion Our study found a new cell type, the DUOX2+ enterocyte that is primarily present in inflamed conditions, and based on their expression profile, potentially perform antigen presentation. Moreover, we highlight that PSC-IBD, but not UC, is characterized by the activation of inflammatory HLA-DRB1+ monocytes, which are likely involved in the activation of CD4+ T cells. Notably, we observed an increased abundance of stem cells in non-inflamed PSC-IBD, possibly linked to the elevated risk of colorectal cancer in PSC-IBD.What is known on the subject?Inflammatory Bowel Disease (IBD) presents in 60–80% of primary sclerosis cholangitis (PSC) patients, termed PSC-IBD. However, the clinical presentation is distinct: patients have 10 times increased risk of colorectal carcinoma as compared to ulcerative colitis (UC) patients, and the conventional IBD treatment regimen is not always effective. The underlying genetic predisposition is also different from general IBD, where PSC-IBD shows a very strong risk association in the HLA-DRB1 region, generally a hallmark of auto-immune disease.What this study adds This study uncovers that PSC-IBD has more autoimmune and UC more inflammatory characteristics. This is supported by the interaction between inflammatory monocytes and CD4+/CD8+ T cells through HLA-DR in PSC-IBD. PSC-IBD patients have pronounced increased activity of inflammatory monocytes, not seen in UC. We find increased stem cell abundance in PSC-IBD. In addition, we show cellular-molecular mechanisms potentially driving the increased risk of carcinoma in PSC-IBD patients offering valuable foundations for targeted therapeutic strategies. In addition, we determined the new DUOX2+ enterocyte.How this research might affect research, practice, or policy This study uncovers that PSC-IBD has more autoimmune characteristics whereas UC is an immune mediated inflammatory disease. This is supported by the specific interaction between inflammatory monocytes and CD4+/CD8+ T cells through HLA-DR in PSC-IBD, while in UC DUOX2+ enterocytes and inflammatory monocytes communicate with innate immune cells, Tregs and CD4+ T cells. Our findings may form new treatment targets for PSC-IBD and IBD in general.Competing Interest StatementThe authors have declared no competing interest.Funding StatementS.S. is supported by a joint fellowship from the University Medical Center Groningen and China Scholarship Council (No. 201906350200), J.B. received a grant from Searave Foundation, R.K.W., E.A.M.F. and K.N.F. received unrestricted research grants from Takeda, R.K.W. received an unrestricted grant from Tramedico and Ferring and is supported by a Diagnostics Grant from the Dutch Digestive Foundation (D16-14). W.T.C.U.V. and E.A.M.F. received a Gastrostart Grant from the Dutch Society of Gastroenterology. E.A.M.F. received a Clinical Fellowship from the ZonMw (90719075), M.G.P.v.d.W is supported by an NWO VIDI 223.041 A.B., P.P., S.d.J., E.B., G.M.P.J.V., F.G.M.K., G.K., M.A.H., and A.V.V. disclose no conflicts of interest.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:University Medical Center Groningen IRB: Gastrointestinal Expression profiles in Intestinal Disease (GE-ID) (NL58808.042.16) The Dutch Federation of University Medical Centres IRB: Parelsnoer IRB (NL24572.018.08)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData will be made available upon request through the EGA server under nr XXX. Scripts may be found here https://github.com/WeersmaLabIBD/PSC_project.IBDInflammatory Bowel DiseasePSCPrimary Sclerosing CholangitisPDC-IBDPrimary sclerosing cholangitis associated Inflammatory bowel diseaseScRNAseqsingle-cell messenger RNA sequencingUCUlcerative colitisI and NIInflamed and Non-InflamedCRCColorectal carcinomaCDCrohn’s diseaseanti-TNFanti-Tumour Necrosis Factor AlphaHCHealthy controlIRBInstitutional Review BoardFCSFoetal Calf SerumPBSPhosphate buffered salineQCQuality controlPCAPrincipal Component AnalysisDAB3,3′-DiaminobenzidineNDPNanoZoomer Digital Pathology